Table . FDA approved medications that mitigate symptoms of Alzheimer's dementia or change the disease progression Analysis of Alzheimer's disease therapeutic clinical trials reveals that around 41% of all trials are not phased (Figure ), including trials such as ones testing medical devices or behavioral interventions. The phase that contains the next largest group of trials is Phase I and Phase II studies, researching the safety and efficacy of newer anti-Alzheimer's disease agents. Over half of all clinical trials in the past 10 years have been completed (Figure ). The status with the next largest group of trials is the recruiting status which is encouraging as new clinical trials are created and carried out to research the treatment of Alzheimer's disease, offering hope to patients worldwide.